Join to View Full Profile
5 Seminole RdSkillman, NJ 08558
Phone+1 609-216-3513
Dr. Lapuerta is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Harvard Medical SchoolClass of 1989
Certifications & Licensure
CA State Medical License 1992 - Present
NJ State Medical License 1996 - 2025
NC State Medical License 1989 - 1991
Clinical Trials
- Clopidogrel and the Optimization of Gastrointestinal Events (COGENT-1) Start of enrollment: 2007 Dec 01
- Pharmacodynamics of CGT 2168 Compared With Plavix® Start of enrollment: 2007 Nov 01
- Study of Telotristat Etiprate (LX1606) in Participants With Symptomatic Carcinoid Syndrome Start of enrollment: 2010 Jun 15
Publications & Presentations
PubMed
- 1 citationsRandomized Phase Ib Clinical Trial of DB-020 Intratympanic Injections to Reduce High-Dose Cisplatin Ototoxicity.Benedict J Panizza, Stephen John O'Leary, Christopher David Hart, Chandra Sai Diwakarla, Catherine Barnett
Journal of Clinical Oncology. 2025-05-22 - 2 citationsTelotristat ethyl reverses myxomatous changes in mice mitral valves.Xinmei Wang, Danielle Kuban-Johnston, Pablo Lapuerta, Carla M R Lacerda
Frontiers in Cardiovascular Medicine. 2022-01-01 - 647 citationsSotagliflozin in Patients with Diabetes and Chronic Kidney Disease.Deepak L. Bhatt, Michael Szarek, Bertram Pitt, Christopher P. Cannon, Lawrence A. Leiter
The New England Journal of Medicine. 2021-01-14
Journal Articles
- Sotagliflozin in Patients with Diabetes and Recent Worsening Heart FailureDeepak L Bhatt, Darren K Mcguire, Jeffrey M Testani, Pablo Lapuerta, Bertram Pitt, The New England Journal of Medicine
Press Mentions
Lexicon Pharmaceuticals Announces Positive 52-Week Results from Sotagliflozin inTandem1 Study Presented at ADA 2018 and Published in Diabetes CareJune 25th, 2018- Lexicon Pharmaceuticals Announces Positive 52-Week Results from Sotagliflozin inTandem2 Study Presented at ADA 2018 and Published in Diabetes CareJune 23rd, 2018
Sotagliflozin (Zynquista): A Novel SGLT MedicationJune 16th, 2018- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
